Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
CVRx, Inc. Market Cap
From what 7 stock analysts predict, the share price for CVRx, Inc. (CVRX) might increase by 22.4% in the next year. This is based on a 12-month average estimation for CVRX. Price targets go from $13 to $20. The majority of stock analysts believe CVRX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 7 Wall Street analysts have assigned CVRX 5 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect CVRx, Inc. to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CVRX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CVRX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Alexander Nowak Craig-Hallum | Buy | $20 | Maintains | Nov 4, 2024 |
| William Plovanic Canaccord Genuity | Buy | $17 | Maintains | Oct 30, 2024 |
| Frank Takkinen Lake Street | Buy | $15 | Maintains | Oct 30, 2024 |
| Matt O'Brien Piper Sandler | Overweight | $16 | Reiterates | Oct 30, 2024 |
| Ross Osborn Cantor Fitzgerald | Overweight | $14 | Reiterates | Oct 23, 2024 |
| Ross Osborn Cantor Fitzgerald | Overweight | $14 | Initiates | Sep 10, 2024 |
| Frank Takkinen Lake Street | Buy | $12 | Reiterates | Aug 26, 2024 |
| William Plovanic Canaccord Genuity | Buy | $15 | Maintains | Jul 30, 2024 |
| Matt O'Brien Piper Sandler | Overweight | $13 | Maintains | Jul 30, 2024 |
| Alexander Nowak Craig-Hallum | Buy | $15 | Maintains | Jul 11, 2024 |
| Frank Takkinen Lake Street | Buy | $12 | Maintains | Jul 11, 2024 |
| Robbie Marcus JP Morgan | Neutral | $13 | Downgrade | May 1, 2024 |
| Alexander Nowak Craig-Hallum | Buy | $23 | Assumes | May 1, 2024 |
| Matt O'Brien Piper Sandler | Overweight | $15 | Maintains | May 1, 2024 |
| William Plovanic Canaccord Genuity | Buy | $14 | Maintains | May 1, 2024 |
| Margaret Kaczor William Blair | Market Perform | Downgrade | May 1, 2024 | |
| Frank Takkinen Lake Street | Buy | $18 | Maintains | May 1, 2024 |
| Robbie Marcus JP Morgan | Overweight | $36 | Maintains | Jan 26, 2024 |
| Matt O'Brien Piper Sandler | Overweight | $33 | Maintains | Jan 26, 2024 |
| Frank Takkinen Lake Street | Buy | $32 | Maintains | Dec 27, 2023 |
When did it IPO
2021
Staff Count
200
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Kevin Hykes
Market Cap
$376.8M
In 2023, CVRX generated $39.3M in revenue, which was a increase of 74.89% from the previous year. This can be seen as a signal that CVRX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CVRx, Inc. will present at the Piper Sandler 36th Annual Healthcare Conference on Dec. 4, 2024, at 3:30 PM ET via webcast.
Why It Matters - CVRx's presentation at a key healthcare conference may provide insights into its growth strategy and product developments, influencing investor sentiment and stock performance.
Wed, 06 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - CVRx's Barostim therapy reports strong clinical success and revenue growth, bolstered by recent CMS reimbursement approvals, though rising SG&A costs may impact profitability.
Why It Matters - CVRx's Barostim therapy demonstrates strong market potential with revenue growth and reimbursement support, but rising costs and possible dilution could impact profitability and investor returns.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - CVRx, Inc. (NASDAQ:CVRX) will hold its Q3 2024 Earnings Conference Call on October 29, 2024, at 4:30 PM ET, featuring key company executives and financial analysts.
Why It Matters - The Q3 earnings call provides insights into CVRx's financial performance, future guidance, and management strategies, influencing investor sentiment and stock valuation.
Tue, 29 Oct 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - CVRx reported a quarterly loss of $0.57 per share, exceeding the Zacks estimate of a $0.45 loss, and worsening from a loss of $0.43 per share a year earlier.
Why It Matters - CVRx's larger-than-expected quarterly loss signals ongoing financial struggles, potentially impacting stock performance and investor confidence.
Mon, 21 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - CVRx shares rose on high trading volume, but recent earnings estimate revisions indicate potential weakness ahead.
Why It Matters - CVRx's share price spike amid high trading volume signals potential market interest, but stagnant earnings estimates may indicate limited future growth, influencing investment decisions.
Fri, 18 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CVRx, Inc. (NASDAQ: CVRX) announced that the AMA has accepted new CPT codes for its Barostim therapy to treat heart failure symptoms, enhancing its market potential.
Why It Matters - The acceptance of new CPT codes for Barostim enhances reimbursement prospects, potentially boosting CVRx's revenue and market position in the heart failure treatment sector.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
